Metformin should be considered in all patients with type 2 diabetes unless contra-indicated
|
|
- Raymond Lyons
- 6 years ago
- Views:
Transcription
1 November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients with type 2 diabetes unless contra-indicated Sulfonylureas are an alternative for patients in whom metformin is either contra-indicated (including those at risk of lactic acidosis) or not tolerated Combination metformin/sulfonylurea is recommended in patients whose blood glucose is controlled inadequately Tight control of blood pressure reduces the risks of microvascular and macrovascular diabetic complications All cardiovascular risk factors diabetes, hypertension, smoking, dyslipidaemia, a previous cardiovascular event need to be managed to optimally reduce the risk of diabetic complications How to manage type 2 diabetes Encourage the patient to adopt lifestyle/dietary measures Lifestyle/dietary measures need to be continued even when drug treatment is required Reduce excess weight through diet and exercise: avoid simple carbohydrates reduce fat intake, particularly saturated fat increase consumption of high-fibre foods increase physical activity, taking into account the presence of ischaemic heart disease or foot problems. For patient materials on healthy eating, visit the Heart Foundation website at Promote smoking cessation Quitting smoking needs to be a goal for anyone with diabetes, especially because of their high risk of experiencing a cardiovascular event. National Prescribing Service Limited ACN An independent, Australian organisation for Quality Use of Medicines
2 Aim to improve blood glucose control Target blood glucose 1,2 Glucose control (as measured by HbA 1c ) progressively declines over time leading to diabetic complications, including mortality 3 5 Consider metformin for all patients with type 2 diabetes, irrespective of their weight, unless contra-indicated Fasting level 6 mmol/l Random level 4 7 mmol/l HbA 1c 7% Any improvement in HbA 1c reduces the incidence of complications, but the greatest benefit occurs in those with higher initial HbA 1c values. Drug therapy often needs to increase over time to maintain glycaemic control: 50% of patients will require more than one antidiabetic drug by 3 years after diagnosis, increasing to 75% by 9 years after diagnosis. 6 Significant benefits have been shown in microvascular (retinopathy, nephropathy, neuropathy) and macrovascular (myocardial infarction, stroke, peripheral vascular disease) morbidity and mortality: in overweight individuals, 10 patients need to be treated with metformin for 10 years to prevent one diabetes-related endpoint; almost five times as many overweight patients (47) need to be treated with sulfonylureas or insulin for 10 years for the same outcome. 5 Other benefits of metformin: no significant weight gain no hypoglycaemia improved lipid profile (reduces LDL and total cholesterol, and triglycerides). 7 Risk of lactic acidosis, a rare but serious adverse effect of metformin, is increased by: doses > 2 g/day renal impairment (a creatinine clearance below 50 ml/min) 8 or any condition which can diminish renal function (e.g. dehydration, surgery) hepatic or cardiac impairment use in the elderly, particularly the very old (> 85 years). 8 Consider sulfonylureas for patients in whom metformin is contra-indicated or who are at risk of developing lactic acidosis Sulfonylureas and insulin have been shown to have similar efficacy in type 2 diabetes; both reduce the risk of microvascular complications while a strong trend showed possible macrovascular benefits: 4 in non-overweight people, 31 patients need to be treated for 10 years with sulfonylureas or insulin to prevent one diabetesrelated endpoint. Choose the sulfonylurea most suitable for the individual: the elderly are at greater risk of hypoglycaemia so short-acting sulfonylureas (gliclazide, glipizide) are preferred to longer-acting sulfonylureas (glibenclamide, glimepiride) avoid glibenclamide or glimepiride in those with renal impairment. When monotherapy is not enough If monotherapy does not provide adequate glycaemic control, a combination of metformin with a sulfonylurea is recommended. For details of this and the place in therapy of the new oral antidiabetic agents, see NPS News 17: Managing type 2 diabetes.
3 Monitor blood glucose The GP: Measure glycated haemoglobin (HbA 1c ) levels 8,9 HbA 1c is a subfraction of haemoglobin that binds glucose. When blood glucose is persistently high, the percentage that binds to haemoglobin increases. HbA 1c reflects blood glucose control over the preceding 1 2 months whereas random blood sampling is a snapshot in time. Measure: at least twice a year in patients who are meeting treatment goals and who have stable glycaemic control 3-monthly in patients whose therapy has changed or who are not meeting glycaemic goals. Note: HbA 1c results vary between laboratories so the same laboratory should be used for repeated testing. The patient: Self monitoring 1,2,8 Take into account the patient s age, need for ideal control and motivation when considering self monitoring. Blood glucose monitoring is more accurate than urine testing and is preferred. The optimal frequency of testing in type 2 diabetes is unknown: testing at different times of the day, 1 2 days a week is suggested the patient should test more frequently when control is likely to be poor (e.g. during illness, after changes in therapy) or when using insulin. Control hypertension Target blood pressure Without proteinuria With proteinuria (1 g/day) < 130/85 mmhg < 125/75 mmhg Managing blood pressure reduces the complications of type 2 diabetes Tight blood pressure control (mean blood pressure over 9 years 144/82 mmhg vs 154/87 mmhg in the less tight control group) has been shown to reduce the risks of microvascular and macrovascular diabetic complications. 10 More than one antihypertensive agent may be needed to maintain blood pressure at target levels by nine years over 60% of patients required at least two antihypertensive drugs to maintain tight control of blood pressure and 29% needed three or more agents. 10 Use ACE inhibitors, beta-blockers, or thiazide diuretics as first-line therapy for hypertension in type 2 diabetes There is no conclusive evidence supporting one antihypertensive drug class over another. The evidence available is derived mainly from post hoc subgroup analyses of patients with diabetes from larger trials not focused on diabetes. Emphasis is given to trials investigating effects on cardiovascular morbidity and mortality. ACE inhibitors have the largest volume of evidence supporting their efficacy in reducing non-fatal and fatal diabetic complications ACE inhibitors reduce urinary albumin excretion in normotensive diabetic patients with microalbuminuria. 12,17 Beta-blockers were as effective as ACE inhibitors in reducing the incidence of diabetic cardiovascular complications. 11 Thiazide diuretics are first-line therapy in mild to moderate hypertension and have proven efficacy in older patients with diabetes. 18
4 Calcium-channel blockers are not recommended as first-line agents in diabetes Calcium-channel blockers (e.g. amlodipine, felodipine, nifedipine) have conflicting evidence, with some trials showing benefits on cardiovascular outcomes 19,20 while other studies have found an increased risk of myocardial infarction, stroke, and death with calcium-channel blockers. 14,15 Note that calcium-channel blockers are generally not used in patients who have had a myocardial infarction. More evidence is required to support the use of angiotensin II receptor antagonists in diabetes Angiotensin II receptor antagonists have, to date, mainly been shown to lower blood pressure and reduce urinary albumin excretion in diabetes; evidence relating to their effect on diabetic morbidity and mortality is emerging. Manage dyslipidaemia Target 2,21 Cholesterol HDL-cholesterol LDL-cholesterol Triglycerides < 5.0 mmol/l 1 mmol/l < 3 mmol/l < 2 mmol/l Diabetes has been classified a coronary heart disease risk equivalent, that is, providing the same level of risk as if the patient has had a prior CHD event 22 Behavioural modification and diet are first-line therapy High triglycerides and low HDL-cholesterol is the most common dyslipidaemia of diabetes. Lipid lowering reduces the incidence of cardiovascular events in people with a history of coronary heart disease (CHD) but no trials have been conducted specifically in diabetic subjects. Measure fasting lipids (preferably without a tourniquet) every 1 2 years if normal or every 3 6 months if either abnormal or on lipid-lowering therapy. 8,23,24 Weight loss, increased physical activity and improved blood glucose control will improve the lipid profile. Assess after a 3 6 months trial. Drug therapy 24 Evidence for secondary prevention with lipid-lowering drugs in diabetes has only been derived from subgroup analyses from the parent trials with small numbers of diabetic people although this evidence is not conclusive, lipid-lowering drugs reduced the number of CHD events in people with diabetes Where hypercholesterolaemia is predominant, use an HMG-CoA reductase inhibitor (statin). Where hypertriglyceridaemia is predominant, use a fibrate (such as gemfibrozil). With mixed hyperlipidaemia, use either a high-dose statin or statin + gemfibrozil. In mixed hyperlipidaemia, combining a fibrate with a statin can cause muscle damage with subsequent rhabdomyolysis specialist advice is recommended.
5 Which patients with type 2 diabetes should be offered aspirin? There is insufficient evidence to define precisely which people with diabetes should receive aspirin prophylactically Aspirin has proven efficacy in the secondary prevention of CHD and stroke in people with diabetes. 19 However, there is little evidence to support routine primary prevention with aspirin in diabetes: a study in individuals without previous myocardial infarction or cerebrovascular disease found that aspirin did not significantly affect cardiovascular mortality or the risk of stroke during the 5-year follow-up period. 29 Whether aspirin should be offered to all patients with type 2 diabetes or only those at higher risk of adverse cardiovascular events remains contentious. In people without contraindications to aspirin use, a dose of mg/day has been recommended as prophylaxis against cardiovascular events 1,30 An increased risk of haemorrhage with long-term aspirin use is a concern: in the HOT study, major fatal and non-fatal bleeds were almost twice as common in the aspirin group as in the placebo group, with gastrointestinal bleeds the most common (57%). 19 More than one antihypertensive drug is often required to achieve satisfactory blood pressure control. In patients where an ACE inhibitor is used with a thiazide diuretic, the use of NSAIDs (including aspirin) can have a triple whammy deleterious effect on renal function. References: 1. Writing Group for Therapeutic Guidelines: Endocrinology. Therapeutic Guidelines: Endocrinology 2nd ed. Melbourne: Therapeutic Guidelines Limited; Holmwood C et al. Diabetes management in general practice. Canberra: National Capital Printing; Stratton IM et al. (UKPDS 35). BMJ 2000;321: UKPDS Group. (UKPDS 33). Lancet 1998;352: UKPDS Group. (UKPDS 34). Lancet 1998;352: Turner RC et al. (UKPDS 49). JAMA 1999;281: DeFronzo RA. Ann Intern Med 1999;131: Australian Medicines Handbook American Diabetes Association. Diabetes Care 2001;24 (Suppl 1):S33 S UKPDS Group. (UKPDS 38). BMJ 1998;317: UKPDS Group. (UKPDS 39). BMJ 1998;317: HOPE Study Investigators. Lancet 2000;355: Hansson L et al. Lancet 1999;353: Estacio RO et al. N Engl J Med 1998;338: Tatti P et al. Diabetes Care 1998;21: Pahor M et al. Diabetes Care 2000;23: Lovell HG. Angiotensin converting enzyme inhibitors in normotensive diabetic patients with microalbuminuria. In: The Cochrane Library, Issue 2, Oxford: Update Software 18. Curb J et al. JAMA 1996;276: Hansson L et al. Lancet 1998;351: Tuomilehto J et al. N Engl J Med 1999;340: National Heart Foundation of Australia. Guide for the use of lipidlowering drugs in adults. (accessed 27 July 2001) 22. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA 2001;285: NSW Health Department. The principles of care and guidelines for the clinical management of diabetes mellitus. Sydney: NSW Health Department; American Diabetes Association. Diabetes Care 2001;24 (Suppl 1):S58 S Pyörälä K et al. Diabetes Care 1997;20: Sacks FM et al. N Engl J Med 1996;335: The LIPID Study Group. N Engl J Med 1998;339: Rubins HB et al. N Engl J Med 1999;341: Steering Committee of the Physicians Health Study Research Group. N Engl J Med 1989;321: American Diabetes Association. Diabetes Care 2001;24 (Suppl 1):S62 S63
Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationSIGN 149 Risk estimation and the prevention of cardiovascular disease. Quick Reference Guide July Evidence
SIGN 149 Risk estimation and the prevention of cardiovascular disease Quick Reference Guide July 2017 Evidence ESTIMATING CARDIOVASCULAR RISK R Individuals with the following risk factors should be considered
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationPrevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan
Prevention And Treatment of Diabetic Nephropathy MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention Tight glucose control reduces the development of diabetic nephropathy Progression
More informationABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour
ABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour Dr Indranil Dasgupta Rationale No national practical
More informationWhy is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
More informationA factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Hypotheses: Among individuals with type 2 diabetes, the risks of major microvascular
More informationComplications of Diabetes mellitus. Dr Bill Young 16 March 2015
Complications of Diabetes mellitus Dr Bill Young 16 March 2015 Complications of diabetes Multi-organ involvement 2 The extent of diabetes complications At diagnosis as many as 50% of patients may have
More informationTreatment to reduce cardiovascular risk: multifactorial management
Treatment to reduce cardiovascular risk: multifactorial management Matteo Anselmino, MD PhD Assistant Professor San Giovanni Battista Hospital Division of Cardiology, Department of Internal Medicine University
More informationDiabetes Control and Complications in Public Hospitals in Malaysia
ORIGINAL ARTICLE Diabetes Control and Complications in Public Hospitals in Malaysia Mafauzy M. FRCP For the Diabcare-Malaysia Study Group, Health Campus, Universiti Sains Malaysia, 16150 Kubang Kerian,
More informationClinical Recommendations: Patients with Periodontitis
The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: Periodontitis and Atherosclerotic Cardiovascular Disease. Friedewald VE, Kornman KS, Beck JD, et al. J Periodontol 2009;
More informationHow to Reduce CVD Complications in Diabetes?
How to Reduce CVD Complications in Diabetes? Chaicharn Deerochanawong M.D. Diabetes and Endocrinology Unit Department of Medicine Rajavithi Hospital, Ministry of Public Health Framingham Heart Study 30-Year
More informationYounger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.
Appendix 2A - Guidance on Management of Hypertension Measurement of blood pressure All adults from 40 years should have blood pressure measured as part of opportunistic cardiovascular risk assessment.
More informationVolume 2; Number 14 September 2008 NICE CLINICAL GUIDELINE 66: TYPE 2 DIABETES THE MANAGEMENT OF TYPE 2 DIABETES (MAY 2008)
Volume 2; Number 14 September 2008 NICE CLINICAL GUIDELINE 66: TYPE 2 DIABETES THE MANAGEMENT OF TYPE 2 DIABETES (MAY 2008) The purpose of this special edition of the PACE Bulletin is to summarize the
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Control of Hypercholesterolaemia and Progression of Diabetic Nephropathy
Control of Hypercholesterolaemia and Progression of Diabetic Nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. All hypercholesterolaemic diabetics
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors
Cardiovascular Risk Factors ROB WALKER (Dunedin, New Zealand) Lipid-lowering therapy in patients with chronic kidney disease Date written: January 2005 Final submission: August 2005 Author: Rob Walker
More informationType 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice.
Type 2 Diabetes Stopping Smoking Consider referral to smoking cessation BMI > 25 kg m² Set a weight loss target of a 5-10% reduction Consider referring for weight management advice Control BP to
More informationDiabetic Dyslipidemia
Diabetic Dyslipidemia Dr R V S N Sarma, M.D., (Internal Medicine), M.Sc., (Canada), Consultant Physician Cardiovascular disease (CVD) is a significant cause of illness, disability, and death among individuals
More informationFive chapters 1. What is CVD prevention 2. Why is CVD prevention needed 3. Who needs CVD prevention 4. How is CVD prevention applied 5. Where should CVD prevention be offered Shorter, more adapted to clinical
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationDiabetic Nephropathy. Objectives:
There are, in truth, no specialties in medicine, since to know fully many of the most important diseases a man must be familiar with their manifestations in many organs. William Osler 1894. Objectives:
More informationGuidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010
Guidelines to assist General Practitioners in the Management of Type 2 Diabetes April 2010 Foreword The guidelines were devised by the Diabetes Day Centre in Beaumont Hospital in consultation with a number
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationRenal Protection Staying on Target
Update Staying on Target James Barton, MD, FRCPC As presented at the University of Saskatchewan's Management of Diabetes & Its Complications (May 2004) Gwen s case Gwen, 49, asks you to take on her primary
More informationCase study: Lean adult with no complications, newly diagnosed with type 2 diabetes
Case study: Lean adult with no complications, newly diagnosed with type 2 diabetes Authored by Clifford Bailey and James LaSalle on behalf of the Global Partnership for Effective Diabetes Management. The
More informationMetabolic Syndrome and Chronic Kidney Disease
Metabolic Syndrome and Chronic Kidney Disease Definition of Metabolic Syndrome National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Abdominal obesity, defined as a waist circumference
More informationAbbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone
Index Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Medication GAD glutamic acid decarboxylase GLP-1 glucagon-like peptide 1 NPH neutral
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationStrategies for the prevention of type 2 diabetes and cardiovascular disease
European Heart Journal Supplements (2005) 7 (Supplement D), D18 D22 doi:10.1093/eurheartj/sui025 Strategies for the prevention of type 2 diabetes and cardiovascular disease Jaakko Tuomilehto 1,2,3 *, Jaana
More information2013 ESC Guidelines on Diabetes, Pre-diabetes and Cardiovascular Diseases Developed in Collaboration with EASD
2013 ES Guidelines on Diabetes, Pre-diabetes and ardiovascular Diseases Developed in ollaboration with ESD Paul Valensi Department of Endocrinology Diabetology Nutrition Jean Verdier Hospital Paris-Nord
More informationData Analysis Plan for assessing clinical efficacy and safety of ER niacin/laropiprant in the HPS2-THRIVE trial
Data Analysis Plan for assessing clinical efficacy and safety of ER niacin/laropiprant in the HPS2-THRIVE trial 1 Background This Data Analysis Plan describes the strategy, rationale and statistical methods
More informationCardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003
Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,
More informationAppendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.
Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix to: Banks E, Crouch SR, Korda RJ, et al. Absolute risk of cardiovascular
More informationADVANCE post trial ObservatioNal Study
Hot Topics in Diabetes 50 th EASD, Vienna 2014 ADVANCE post trial ObservatioNal Study Sophia Zoungas The George Institute The University of Sydney Rationale and Study Design Sophia Zoungas The George Institute
More informationMetformin Hydrochloride
Metformin Hydrochloride 500 mg, 850 mg, 500 mg LA and 750 mg LA Tablet Description Informet is a preparation of metformin hydrochloride that belongs to a biguanide class of oral antidiabetic drugs. Metformin
More informationhypertension Head of prevention and control of CVD disease office Ministry of heath
hypertension t. Samavat MD,Cadiologist,MPH Head of prevention and control of CVD disease office Ministry of heath RECOMMENDATIONS FOR HYPERTENSION DIAGNOSIS, ASSESSMENT, AND TREATMENT Definition of hypertension
More informationThe United Kingdom Prospective
Professional issues The UKPDS: a nursing perspective Marilyn Gallichan Article points 1The UKPDS followed up more than 5000 patients from 23 centres for a median of 10 years. 2The findings provide a powerful
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Specific effects of calcium channel blockers in diabetic nephropathy GUIDELINES
Specific effects of calcium channel blockers in diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. Non-dihydropyridine calcium channel
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Blood Pressure Control role of specific antihypertensives
Blood Pressure Control role of specific antihypertensives Date written: May 2005 Final submission: October 2005 Author: Adrian Gillian GUIDELINES a. Regimens that include angiotensin-converting enzyme
More informationAPPENDIX 2F Management of Cholesterol
Patients with established CVD: Coronary heart disease Cerebrovascular disease Peripheral vascular disease APPEDIX 2F Management of Cholesterol Patients at high risk of cardiovascular events: Chronic kidney
More informationPractical Diabetes. Nic Crook. (and don t use so many charts) Kuirau Specialists 1239 Ranolf Street Rotorua. Rotorua Hospital Private Bag 3023 Rotorua
Practical Diabetes (and don t use so many charts) Nic Crook Rotorua Hospital Private Bag 3023 Rotorua Kuirau Specialists 1239 Ranolf Street Rotorua Worldwide rates of diabetes mellitus: predictions 80
More informationKidney and heart: dangerous liaisons. Luis M. RUILOPE (Madrid, Spain)
Kidney and heart: dangerous liaisons Luis M. RUILOPE (Madrid, Spain) Type 2 diabetes and renal disease: impact on cardiovascular outcomes The "heavyweights" of modifiable CVD risk factors Hypertension
More informationCardiovascular Management of a Patient with Diabetes
Cardiovascular Management of a Patient with Diabetes Dr Jeremy Krebs Clinical Leader Endocrinology and Diabetes Wellington Hospital Summary People with diabetes take a lot of medication Compliance and
More information2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension.
2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension Writing Group: Background Hypertension worldwide causes 7.1 million premature
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationComplications of Diabetes: Screening and Prevention
Complications of Diabetes: Screening and Prevention Dr Steve Cleland Consultant Physician GGH and QEUH Diabetes Staff Education Course June 17 Diabetic Complications Microvascular: Retinopathy Nephropathy
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationPrimary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group
Primary and Secondary Prevention of Cardiovascular Disease Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group AHA Diet and Lifestyle Recommendations Balance calorie intake and physical activity to
More informationSwindon Diabetes Guidelines: Management of Chronic Kidney Disease Associated with Diabetes Mellitus
Swindon Diabetes Guidelines: Management of Chronic Kidney Disease Associated with Diabetes Mellitus 1 Contents Executive Summary... 3 How to Screen for Diabetic Nephropathy... 4 What to Measure... 4 Frequency
More informationVA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005
VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationDiabetes Overview. How Food is Digested
Diabetes Overview You are The Teacher, The Coach and the Fan Pathophysiology of Diabetes Complications Know the Numbers Treatment Can Good Control Make a Difference? Can Tight Control Be too Tight? How
More informationChronic Benefit Application Form Cardiovascular Disease and Diabetes
Chronic Benefit Application Form Cardiovascular Disease and Diabetes 19 West Street, Houghton, South Africa, 2198 Postnet Suite 411, Private Bag X1, Melrose Arch, 2076 Tel: +27 (11) 715 3000 Fax: +27 (11)
More informationTRANSPARENCY COMMITTEE OPINION. 29 April 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 April 2009 VELMETIA 50 mg/850 mg, film-coated tablets B/56 (CIP code: 386 778-0) VELMETIA 50 mg/1 000 mg, film-coated
More informationVolume 2; Number 11 July 2008
Volume 2; Number 11 July 2008 CONTENTS Page 1 NICE Clinical Guideline 67: Lipid Modification (May 2008) Page 7 NICE Technology Appraisal 132: Ezetimibe for the treatment of primary (heterozygous familial
More informationGuidelines for Integrated Management of. Cardiovascular Diseases and Diabetes. in Clinics and Ri-hospitals
Guidelines for Integrated Management of Cardiovascular Diseases and Diabetes in Clinics and Ri-hospitals Ministry of Public Health DPR Korea January 2013 Rationale ncommunicable diseases such as cardiovascular
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationDiabetes: a key problem in elderly
Diabetes: a key problem in elderly 노인인구의급격한증가 자료 : 통계청. 고령자통계. 2005 Prevalence of diagnosed and undiagnosed diabetes and IGT by age and sex, KOREA Park Y, et al. Diabetes Care. 18(4):545-8, 1995 2005 년도우리나라당뇨병유병률
More informationThe State of Play of Diabetes Indicators
The State of Play of Diabetes Indicators South Australian and National Information Catherine Chittleborough Janet Grant Anne Taylor April 2003 Diabetes Clearing House Population Research and Outcome Studies
More informationDiabetes in the Elderly 1, 2, 3
Diabetes in the Elderly 1, 2, 3 WF Mollentze Feb 2010 Diabetes in the elderly differs from diabetes in younger people Prevalence: o Diabetes increases with age affecting approximately 10% of people over
More informationCEDIAMATE Metformin Tablets USP 500 mg
CEDIAMATE Metformin Tablets USP 500 mg COMPOSITION: Cediamate Each un-coated tablet contains: Metformin Hydrochloride USP Excipients 500 mg Q.S PHARMACOLOGY: Pharmacotherapeutic group: Blood Glucose lowering
More informationFenofibrate interaction
Search Query (DRUGGENERICNAME = Avandia ) AND (RECORDTYPE = Case Report ) 1 Documents Exported 1. Fenofibrate interaction First report of an interaction with concomitant rosiglitazone leading to muscular
More informationFinding the sweet spot: Individualized targets for older adults with Type 2 DM
Finding the sweet spot: Individualized targets for older adults with Type 2 DM Samuel C. Durso, M.D., M.B.A. Mason F. Lord Professor of Medicine Director, Division of Geriatric Medicine and Gerontology
More informationDIABETES MEASURES GROUP OVERVIEW
2014 PQRS OPTIONS F MEASURES GROUPS: DIABETES MEASURES GROUP OVERVIEW 2014 PQRS MEASURES IN DIABETES MEASURES GROUP: #1. Diabetes: Hemoglobin A1c Poor Control #2. Diabetes: Low Density Lipoprotein (LDL-C)
More informationMOLINA HEALTHCARE OF CALIFORNIA
MOLINA HEALTHCARE OF CALIFORNIA HIGH BLOOD CHOLESTEROL IN ADULTS GUIDELINE Molina Healthcare of California has adopted the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationRENAAL, IRMA-2 and IDNT. Three featured trials linking a disease spectrum IDNT RENAAL. Death IRMA 2
Treatment of Diabetic Nephropathy and Proteinuria Background End stage renal disease is a major cause of death and disability among diabetics BP reduction is important to slow the progression of diabetic
More informationNew indicators to be added to the NICE menu for the QOF and amendments to existing indicators
New indicators to be added to the for the QOF and amendments to existing indicators 1 st September 2015 Version 1.1 This document was originally published on 3 rd August 2015, it has since been updated.
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationManagement of DM in Older Adults: It s not all about sugar! Who needs treatment for DM? Peggy Odegard, Pharm.D., BCPS, CDE
Management of DM in Older Adults: It s not all about sugar! Peggy Odegard, Pharm.D., BCPS, CDE Who needs treatment for DM? 87 year old, frail male with moderately severe dementia living in NH with persistent
More informationReducing proteinuria
Date written: May 2005 Final submission: October 2005 Author: Adrian Gillin Reducing proteinuria GUIDELINES a. The beneficial effect of treatment regimens that include angiotensinconverting enzyme inhibitors
More informationDRUG UTILIZATION PATTERNS OF ANTIHYPERTENSIVES IN VARIOUS WARDS IN A TERTIARY CARE HOSPITAL IN TAMILNADU
Original Article DRUG UTILIZATION PATTERNS OF ANTIHYPERTENSIVES IN VARIOUS WARDS IN A TERTIARY CARE HOSPITAL IN TAMILNADU V.Gowri 1, K.Punnagai, K.Vijaybabu 3, Dr.Darling Chellathai 4 1 Assistant Professor
More informationALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic
1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker
More information( Diabetes mellitus, DM ) ( Hyperlipidemia ) ( Cardiovascular disease, CVD )
005 6 69-74 40 mg/dl > 50 mg/dl) (00 mg/dl < 00 mg/dl(.6 mmol/l) 30-40% < 70 mg/dl 40 mg/dl 00 9 mg/dl fibric acid derivative niacin statin fibrate statin niacin ( ) ( Diabetes mellitus,
More informationDiabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More informationLong-Term Complications of Diabetes Mellitus Macrovascular Complication
Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent
More informationClinical Practice Guideline Key Points
Clinical Practice Guideline Key Points Clinical Practice Guideline 2008 Key Points Diabetes Mellitus Provided by: Highmark Endocrinology Clinical Quality Improvement Committee In accordance with Highmark
More informationSCIENTIFIC STUDY REPORT
PAGE 1 18-NOV-2016 SCIENTIFIC STUDY REPORT Study Title: Real-Life Effectiveness and Care Patterns of Diabetes Management The RECAP-DM Study 1 EXECUTIVE SUMMARY Introduction: Despite the well-established
More informationIndex. Note: Page numbers of article titles are in boldface type.
Heart Failure Clin 2 (2006) 101 105 Index Note: Page numbers of article titles are in boldface type. A ACE inhibitors, in diabetic hypertension, 30 31 Adipokines, cardiovascular events related to, 6 Advanced
More informationBlood Pressure Treatment Goals
Blood Pressure Treatment Goals Kenneth Izuora, MD, MBA, FACE Associate Professor UNLV School of Medicine November 18, 2017 Learning Objectives Discuss the recent studies on treating hypertension Review
More informationDiabetes Complications Guideline Based Screening, Management, and Referral
Diabetes Complications Guideline Based Screening, Management, and Referral Eric L. Johnson, M.D. Associate Professor Department of Family and Community Medicine Assistant Medical Director Altru Diabetes
More informationThe problem of uncontrolled hypertension
(2002) 16, S3 S8 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh The problem of uncontrolled hypertension Department of Public Health and Clinical Medicine, Norrlands
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationBy Prof. Khaled El-Rabat
What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating
More informationDiabetes in Renal Patients. Contents. Understanding Diabetic Nephropathy
Diabetes in Renal Patients Contents Understanding Diabetic Nephropathy What effect does CKD have on a patient s diabetic control? Diabetic Drugs in CKD and Dialysis Patients Hyper and Hypoglycaemia in
More information2013 Hypertension Measure Group Patient Visit Form
Please complete the form below for 20 or more unique patients meeting patient sample criteria for the measure group for the current reporting year. A majority (11 or more) patients must be Medicare Part
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationcardiovascular risk in elderly people Managing DECISION TO PRESCRIBE keyword: elderlycardio What am I trying to achieve?
Managing cardiovascular risk in elderly people www.bpac.org.nz keyword: elderlycardio DECISION TO PRESCRIBE What am I trying to achieve? Prevent possible future cardiovascular events. Maintain quality
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationUpdate on CVD and Microvascular Complications in T2D
Update on CVD and Microvascular Complications in T2D Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationChallenges in type 2 diabetes control: slipping control and weight gain
control Earn 3 CPD Points online Case study Challenges in type 2 diabetes control: slipping control and weight gain Presenter Dr Sedeshan Govender Specialist Physician, Endocrinologist and Diabetologists
More informationBEST PRACTICE MANAGEMENT: CARDIOVASCULAR RISKS
BEST PRACTICE MANAGEMENT: CARDIOVASCULAR RISKS Neil R Poulter ICCH, Imperial College London BHIVA: October 10th, 2008 Background CVD is the biggest single killer in the world CVD rates are increasing High
More informationManagement of early chronic kidney disease
Management of early chronic kidney disease GREENLANE SUMMER GP SYMPOSIUM 2018 Jonathan Hsiao Renal and General Physician Introduction A growing public health problem in NZ and throughout the world. Unknown
More informationCardiovascular risk reduction in diabetes Lipids (NICE CG181)
Cardiovascular risk reduction in diabetes Lipids (NICE CG181) Primary Prevention T1DM Offer Atorvastatin 20mg if >40 years old Diabetes duration >10 years Established nephropathy Other CVS risk factors
More information